| Item Type | Name |
|
Concept
|
Platelet Count
|
|
Academic Article
|
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
|
|
Academic Article
|
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.
|
|
Academic Article
|
Splenectomy in the accelerated or blastic phase of chronic myelogenous leukemia: a single-institution, 25-year experience.
|
|
Academic Article
|
Evaluation and comparison of three mobilization methods for the collection of granulocytes.
|
|
Academic Article
|
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
|
|
Academic Article
|
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
|
|
Academic Article
|
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
|
|
Academic Article
|
Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.
|
|
Academic Article
|
Piperazinedione, total body irradiation, and autologous bone marrow transplantation in chronic myelogenous leukemia.
|
|
Academic Article
|
High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
|
|
Academic Article
|
Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
|
|
Academic Article
|
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
|
|
Academic Article
|
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
|
|
Academic Article
|
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
|
|
Academic Article
|
Phase I study of oral topotecan in hematological malignancies.
|
|
Academic Article
|
A prognostic score for patients with lower risk myelodysplastic syndrome.
|
|
Academic Article
|
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Ruxolitinib for myelofibrosis--an update of its clinical effects.
|
|
Academic Article
|
Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
|
|
Academic Article
|
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
|
|
Academic Article
|
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).
|
|
Academic Article
|
Clinical investigation of human alpha interferon in chronic myelogenous leukemia.
|
|
Academic Article
|
Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
|
|
Academic Article
|
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
|
|
Academic Article
|
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
|
|
Academic Article
|
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
|
|
Academic Article
|
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
|
|
Academic Article
|
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
|
|
Academic Article
|
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
|
|
Academic Article
|
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
|
|
Academic Article
|
High-dose chemotherapy and unpurged autologous bone marrow transplantation for acute leukemia in second or subsequent remission.
|
|
Academic Article
|
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
|
|
Academic Article
|
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Outcome of adults with acute lymphocytic leukemia after second salvage therapy.
|
|
Academic Article
|
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
|
|
Academic Article
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
|
|
Academic Article
|
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
|
|
Academic Article
|
Clinical outcomes in adult patients with aplastic anemia: A single institution experience.
|
|
Academic Article
|
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
|
|
Academic Article
|
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
|
|
Academic Article
|
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
|
|
Academic Article
|
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
|
|
Academic Article
|
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
|